Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Lana Zhovtis-Ryerson"'
Autor:
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1385-1401 (2024)
Abstract Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient
Externí odkaz:
https://doaj.org/article/b321bac547dd4d7899d298075a610cb1
Autor:
Lana Zhovtis Ryerson, John Foley, Ilya Kister, Gary Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Liesel DSilva, Susie Sinks, Nolan Campbell, Tyler Lasky, Karthik Bodhinathan
Publikováno v:
Thursday, April 27.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70b51028ccf92a0474a84b0bf5784549
https://doi.org/10.1212/wnl.0000000000202006
https://doi.org/10.1212/wnl.0000000000202006
Autor:
Lana Zhovtis Ryerson, John F Foley, Gilles Defer, Jeffrey A Cohen, Douglas L Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Susie Sinks, Robert Kuhelj, Karthik Bodhinathan, Tyler Lasky
Publikováno v:
Multiple Sclerosis and Related Disorders, 72:104561. Elsevier
Ryerson, L Z, Foley, J F, Defer, G, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Sinks, S, Kuhelj, R, Bodhinathan, K & Lasky, T 2023, ' Exploratory clinical efficacy and patient-reported outcomes from NOVA : A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis ', Multiple Sclerosis and Related Disorders, vol. 72, 104561 . https://doi.org/10.1016/j.msard.2023.104561
Ryerson, L Z, Foley, J F, Defer, G, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Sinks, S, Kuhelj, R, Bodhinathan, K & Lasky, T 2023, ' Exploratory clinical efficacy and patient-reported outcomes from NOVA : A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis ', Multiple Sclerosis and Related Disorders, vol. 72, 104561 . https://doi.org/10.1016/j.msard.2023.104561
Background: Natalizumab (TYSABRI®) 300 mg administered intravenously every-4-weeks (Q4W) is approved for treatment of relapsing-remitting multiple sclerosis but is associated with increased risk of progressive multifocal leukoencephalopathy (PML). E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf2a3f4eff45dd5b8ed3702ad43ece9
https://doi.org/10.1016/j.msard.2023.104561
https://doi.org/10.1016/j.msard.2023.104561
Publikováno v:
Multiple sclerosis and related disorders. 70
B-cell depleting therapies such as rituximab and ocrelizumab are widely used for the treatment of Multiple Sclerosis but have increased risks of adverse reactions compared to earlier MS therapies. One rarely reported reaction is pyoderma gangrenosum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f38051e258569638ef69ee01e47558e
https://pubmed.ncbi.nlm.nih.gov/36580875
https://pubmed.ncbi.nlm.nih.gov/36580875
Autor:
Kathryn C. Fitzgerald, Karla Gray-Roncal, Sandra D. Cassard, Lana Zhovtis Ryerson, Kedar R Mahajan, Ellen M. Mowry, Robert T. Naismith, Daniel Ontaneda, Leigh Charvet, Wanda Castro-Borrero
Publikováno v:
Neurology
ObjectiveTo compare clinical and imaging features of multiple sclerosis (MS) severity between Black Americans (BAs) and White Americans (WAs) and to evaluate the role of socioeconomic status.MethodsWe compared BA and WA participants in the Multiple S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6b9c251c4c02eae22d2be023c3e226
https://doi.org/10.1212/wnl.0000000000012362
https://doi.org/10.1212/wnl.0000000000012362
Autor:
Lana Zhovtis Ryerson, Rivka Green, Gladyne Confident, Krupa Pandey, Benjamin Richter, Tamar Bacon, Carrie Sammarco, Lisa Laing, Jennifer Kalina, Ilya Kister
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Background: Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing–remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White p
Externí odkaz:
https://doaj.org/article/dce2aa5c6c9a48299afca03f33b40cd3
Autor:
Ilya Kister, Yury Patskovsky, Ryan Curtin, Jinglan Pei, Katherine Perdomo, Zoe Rimler, Iryna Voloshyna, Marie I. Samanovic, Amber R. Cornelius, Yogambigai Velmurugu, Samantha Nyovanie, Joseph J. Kim, Ethan Tardio, Tamar E. Bacon, Lana Zhovtis Ryerson, Pranil Raut, Rosetta Pedotti, Kathleen Hawker, Catarina Raposo, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Mark J. Mulligan, Michelle Krogsgaard, Gregg J. Silverman
ObjectiveTo determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection.MethodsMS patients aged 18-60 were evaluated for anti-nucleocapsid and anti-Spike RBD antibody with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07123a16a2d5d1d7243ba7e641329812
https://doi.org/10.1101/2022.01.10.22268752
https://doi.org/10.1101/2022.01.10.22268752
Autor:
John F Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen, Douglas L Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell, Anneke van der Walt, Christopher Dwyer, Katherine Buzzard, Judith Spies, John Parratt, Vincent van Pesch, Barbara Willekens, Gaetano Perrotta, Emmanuel Bartholomé, Francois Grand'Maison, Francois Jacques, Paul Giacomini, Reza Vosoughi, Jean-Marc Girard, Jerome de Seze, Christine Lebrun Frenay, Aurelie Ruet, David-Axel Laplaud, Gerd Reifschneider, Bert Wagner, Sebastian Rauer, Refik Pul, Maria Seipelt, Achim Berthele, Luisa Klotz, Boris-Alexander Kallmann, Friedemann Paul, Anat Achiron, Giacomo Lus, Diego Centonze, Francesco Patti, Luigi Grimaldi, Raymond Hupperts, Stephan Frequin, Jiske Fermont, Sara Eichau Madueno, Ana Maria Alonso Torres, Lucienne Costa-Frossard França, Jose Eustasio Meca-Lallana, Luis Brieva Ruiz, Owen Pearson, David Rog, Nikolaos Evangelou, Azza Ismail, Ellen Lathi, Edward Fox, Thomas Leist, Jacob Sloane, Gregory Wu, Bhupendra Khatri, Brian Steingo, Ben Thrower, Mark Gudesblatt, Jonathan Calkwood, Daniel Bandari, John Scagnelli, Christopher Laganke, Derrick Robertson, Lucas Kipp, Martin Belkin, Stanley Cohan, Lawrence Goldstick, Ardith Courtney, Wendy Vargas, Andrew Sylvester, Jayshri Srinivasan, Meena Kannan, Maryann Picone, Jeffrey English, Salvatore Napoli, Roumen Balabanov, Islam Zaydan, Jacqueline Nicholas, Jeffrey Kaplan, Fred Lublin, Emily Riser, Tamara Miller, Enrique Alvarez, Sibyl Wray, Jeffrey Gross, Siddharama Pawate, Carrie Hersh, Lucas McCarthy, Heidi Crayton, Jennifer Graves
Publikováno v:
Foley, J F, Defer, G, Ryerson, L Z, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Smirnakis, K, Xiao, S, Kong, G, NOVA study investigators, Kuhelj, R & Campbell, N 2022, ' Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial ', Lancet Neurology, vol. 21, no. 7, pp. 608-619 . https://doi.org/10.1016/S1474-4422(22)00143-0
The lancet neurology
Lancet Neurology, 21(7), 608-619. Lancet Publishing Group
The lancet neurology
Lancet Neurology, 21(7), 608-619. Lancet Publishing Group
Background: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing is asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f21f3144ffc325fc4897a835c552966d
https://hdl.handle.net/20.500.11769/548322
https://hdl.handle.net/20.500.11769/548322
Autor:
Lana Zhovtis Ryerson, Robert T. Naismith, Lauren B. Krupp, Leigh E. Charvet, Shirley Liao, Elizabeth Fisher, Carl de Moor, James R. Williams, Nolan Campbell
Publikováno v:
Multiple sclerosis and related disorders. 58
Extended interval dosing (EID; average dosing interval approximately every 6 weeks) of natalizumab is associated with significantly lower risk of progressive multifocal leukoencephalopathy than standard interval dosing (SID; every 4 weeks) in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d69bfc35cb7eb63331265e30433c43cd
https://pubmed.ncbi.nlm.nih.gov/35051898
https://pubmed.ncbi.nlm.nih.gov/35051898
Autor:
Eugene O. Major, Lana Zhovtis Ryerson
Publikováno v:
Drug Discovery Today: Disease Models. 32:13-19
Progressive multifocal leukoencephalopathy (PML), is an opportunistic brain infection that is caused by the JC virus. It usually occurs in patients with an underlying disease and therapies used to treat such diseases that inhibit normal immune system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::477ce8fd3ade1551d6f8607a726fd357
https://doi.org/10.1016/j.ddmod.2020.02.002
https://doi.org/10.1016/j.ddmod.2020.02.002